Table 6.
Heterogeneity and subgroup analyses of each included study
| Kanchanatawan et al. | Dai et al. | Xu et al. | Shen et al. | ||||
|---|---|---|---|---|---|---|---|
| PRP v HA | PRP v placebo | PRP v HA | PRP v placebo | PRP v HA | PRP v placebo | PRP v Control | |
| Statistical heterogeneity analysis | + | + | + | + | |||
| Subgroup or sensitivity analysis | |||||||
| Primary study quality | + | + | + | + | |||
| Age | – | – | – | – | |||
| Gender | – | – | – | – | |||
| OA grade | – | – | – | – | |||
| WOMAC total score | + (≤ 1 year) | + (≤ 1 year) | + (6, 12 months) | +(6, 12 months) | + (3, 6, 12 months) | +(6 months) | +(3, 6, 12 months) |
| WOMAC pain score | + (≤ 1 year) | + (≤ 1 year) | + (6, 12 months) | +(6, 12 months) | – | – | +(3, 6, 12 months) |
| WOMAC functional score | + (≤ 1 year) | + (≤ 1 year) | + (6, 12 months) | +(6, 12 months) | – | – | +(3, 6, 12 months) |
| Lequesne score | + (≤ 1 year) | – | + (6, 12 months) | – | + (6 months) | – | – |
| IKDC score | + (≤ 1 year) | – | + (6, 12 months) | – | + (6 months) | +(6 months) | – |
| VAS score | + (≤ 1 year) | – | – | – | + (6 months) | – | – |
| Adverse events | + | + | + | + | – | – | + |
| No. of PRP injection (1 or ≥ 2); PRP spinning approach (single or double); mean platelet concentration (> or < 5*baseline); LP or LR PRP; with an activator or not, risk of bias | – | + | – | – | |||